简报:抗人类T淋巴细胞病毒I型抗体阳性类风湿关节炎患者中肿瘤坏死因子抑制剂疗效减弱
在日本西南部HTLV-I感染流行区开展观察性研究,585例新启用TNF抑制剂作为首个生物制剂的RA患者中50例(8.5%)抗HTLV-I抗体阳性。抗HTLV-I抗体阴性患者EULAR缓解率显著更优(P=0.0277),多因素回归显示抗体状态与EULAR缓解率及DAS28-ESR变化显著相关,在ACPA阴性者中尤为突出。24周治疗期间无ATL或HAM发生,但长期风险未知。
要点
- 抗HTLV-I抗体阳性RA患者TNF抑制剂疗效可能减弱,EULAR缓解率显著低于抗体阴性者(P=0.0277)。
- 抗HTLV-I抗体状态与EULAR缓解率及DAS28-ESR变化显著相关,ACPA阴性者中尤为突出。
- 24周TNF抑制剂治疗期间无ATL或HAM发生,但长期风险未知。
核心结论
- 抗HTLV-I抗体阳性RA患者中TNF抑制剂疗效可能减弱。
- 24周使用TNF抑制剂期间未发生ATL或HAM,但长期风险未知。
研究设计与样本
- 在日本西南部HTLV-I感染流行区开展观察性研究,纳入585例新启用TNF抑制剂作为首个生物制剂改善病情抗风湿药的RA患者。
主要发现
- 50例(8.5%)抗HTLV-I抗体阳性,该组入组时年龄显著高于抗HTLV-I抗体阴性患者(n=535)。
- 全部患者中位DAS28-ESR为5.21,82%为ACPA阳性,TNF抑制剂24周持续率为89%。
- 两组中位DAS28-ESR在24周均显著下降,抗HTLV-I抗体阴性患者EULAR缓解率显著更优(P=0.0277)。
- 多因素回归分析显示抗HTLV-I抗体状态与EULAR缓解率及DAS28-ESR变化显著相关,在ACPA阴性者中尤为突出。
- 24周治疗期间无患者发生ATL或HAM。
关键数值与推荐
- 抗HTLV-I抗体阳性50例(8.5%),抗HTLV-I抗体阴性535例。
- 全部患者中位DAS28-ESR为5.21,82%为ACPA阳性。
- TNF抑制剂24周持续率为89%。
- 抗HTLV-I抗体阴性患者EULAR缓解率显著优于抗体阳性患者(P=0.0277)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出TNF抑制剂使用24周时未发生ATL或HAM,但长期风险未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness of tumor necrosis factor (TNF) inhibitors for the treatment of human T lymphotropic virus type I (HTLV-I)-positive patients with rheumatoid arthritis (RA) in an area endemic for HTLV-I infection. METHODS: We conducted an observational study of 585 RA patients in whom TNF inhibitors were newly introduced as a first biologic disease-modifying antirheumatic drug in an area in southwestern Japan that is endemic for HTLV-I infection. RESULTS: Fifty patients (8.5%) were anti-HTLV-I antibody-positive. The ages of the patients in this group were significantly higher at entry compared with the ages of patients who were anti-HTLV-I antibody-negative (n = 535). The median Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR) was 5.21. Among the total group of patients, 82% were anti-citrullinated protein antibody (ACPA)-positive. The persistence rate of TNF inhibitors at 24 weeks was 89%. The median DAS28-ESR was significantly decreased at 24 weeks in each group. The European League Against Rheumatism (EULAR) response rate was significantly better in the anti-HTLV-I antibody-negative patients (P = 0.0277). Multiple regression analysis demonstrated that anti-HTLV-I antibody status was significantly associated with the EULAR response rate and change in the DAS28-ESR and was prominent especially in the ACPA-negative subjects. No patients developed adult T cell leukemia/lymphoma (ATL) or HTLV-I-associated myelopathy (HAM) during the 24-week treatment period. CONCLUSION: The efficacy of TNF inhibitors may be attenuated in anti-HTLV-I antibody-positive patients with RA. ATL and HAM did not develop when TNF inhibitors were used for 24 weeks, but the long-term risk is not known.
引用
- Suzuki T, Fukui S, Umekita K, et al. Brief Report: Attenuated Effectiveness of Tumor Necrosis Factor Inhibitors for Anti-Human T Lymphotropic Virus Type I Antibody-Positive Rheumatoid Arthritis. Arthritis Rheumatol. 2018. PMID: 29471588. doi:10.1002/art.40461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。